Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2010
08/12/2010US20100204162 Substrate reduction therapy
08/12/2010US20100204160 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
08/12/2010US20100204158 Combination of splenopentin and thymopentin and the use thereof in medicine
08/12/2010US20100204157 Use of a peptide as a therapeutic agent
08/12/2010US20100204156 Use of thymopentin as a therapeutic agent
08/12/2010US20100204155 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents
08/12/2010US20100204154 Use of the peptide rfmwmr as a therapeutic agent
08/12/2010US20100204153 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection
08/12/2010US20100204152 Use of gluten exorphin c : as a therapeutic agent
08/12/2010US20100204151 Use of a peptide as a therapeutic agent
08/12/2010US20100204149 Use of octreotide as a therapeutic agent
08/12/2010US20100204145 Use of a peptide as a therapeutic agent
08/12/2010US20100204144 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
08/12/2010US20100204143 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
08/12/2010US20100204142 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
08/12/2010US20100204141 Use of bpp-b as a therapeutic agent
08/12/2010US20100204140 Use of a peptide as a therapeutic agent
08/12/2010US20100204139 Use of gonadorelin as a therapeutic agent
08/12/2010US20100204138 Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
08/12/2010US20100204136 Use of a peptide as a therapeutic agent
08/12/2010US20100204135 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
08/12/2010US20100204134 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent
08/12/2010US20100204132 THERAPEUTIC USES OF PEPTIDES YSAYPDSVPMMS and WMNSTGFTKVCGAPPC
08/12/2010US20100204131 Use of a peptide as a therapeutic agent
08/12/2010US20100204130 Use of human neuropeptide as a therapeutic agent
08/12/2010US20100204124 Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
08/12/2010US20100204123 Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
08/12/2010US20100204119 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5h)-yl phenyl derivatives
08/12/2010US20100204118 Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents
08/12/2010US20100204117 Cgrp as a therapeutic agent
08/12/2010US20100204116 Use of calcitonin as anti-angiogenic agent
08/12/2010US20100204115 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents
08/12/2010US20100204114 Use of a galanin peptide as a therapeutic agent
08/12/2010US20100204113 Use of stresscopin-related peptide as a therapeutic agent
08/12/2010US20100204112 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
08/12/2010US20100204111 Astressin and beta- endorphin for use as therapeutic agents
08/12/2010US20100204110 Use of a peptide as a therapeutic agent
08/12/2010US20100204109 Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
08/12/2010US20100204108 Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents
08/12/2010US20100204107 Use of urodilatin as a therapeutic agent
08/12/2010US20100204105 Glucagon analogues
08/12/2010US20100204103 Helical synthetic peptides that stimulate cellular cholesterol efflux
08/12/2010US20100204099 Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
08/12/2010US20100204090 Use of a peptide as a therapeutic agent
08/12/2010US20100204089 Phosphorylated pyrone analogs and methods
08/12/2010US20100203628 Novel modified galectin 9 proteins and use thereof
08/12/2010US20100203176 Method for reducing weight in a subject
08/12/2010US20100203174 Pet food composition for regulating body weight and preventing obesity and related disorders in pets
08/12/2010US20100203117 Anti-adipogenic compositions containing piper betle and dolichos biflorus
08/12/2010US20100203099 Multi-domain amphipathic helical peptides and methods of their use
08/12/2010US20100203078 Anti-obese compositions containing holoptelea integrifolia extracts
08/12/2010US20100203052 Binding domain-immunoglobulin fusion proteins
08/12/2010US20100203032 Orlistat compositions
08/12/2010US20100203026 Probiotics for inducing satiety and/or satiation
08/12/2010US20100203025 Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation
08/12/2010US20100203016 Pregnancy hormone combination for treatment of autoimmune diseases
08/12/2010US20100203014 Zwitterionic buffered acidic peptide and protein formulations
08/12/2010US20100203005 Transdermal compositions
08/12/2010US20100202980 Herbal Compositions for the Treatment of Diabetes and/or Conditions Associated Therewith
08/12/2010CA2750870A1 Method for coating microspheres onto a flexible material
08/12/2010CA2750704A1 Phenylimidazole compounds
08/12/2010CA2750517A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
08/12/2010CA2750459A1 Compositions and methods for inhibiting expression of ptp1b genes
08/12/2010CA2744946A1 Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
08/11/2010EP2216409A1 Albumin fusion proteins
08/11/2010EP2216330A1 Oxadiazolidinedione compound
08/11/2010EP2216023A1 Condensed pyridine derivative and use thereof
08/11/2010EP2215090A1 Purine derivatives useful as pi3 kinase inhibitors
08/11/2010EP2215089A1 [1h- pyrazolo [3, 4-b]pyridine-4-yl]-phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
08/11/2010EP2215078A1 Azetidinyl g-protein coupled receptor agonists
08/11/2010EP2215077A1 Azetidinyl g-protein coupled receptor agonists
08/11/2010EP2215068A1 Antidiabetic tricyclic compounds
08/11/2010EP2215066A1 Amide derivatives as sirtuin modulators
08/11/2010EP2215052A1 Desferrioxamine conjugates, derivatives and analogues
08/11/2010EP2214698A2 Use of compounds activating sirt-3 for mimicking exercise
08/11/2010EP2214690A1 Melanocortin receptor binding mimetibodies, compositions, methods and uses
08/11/2010EP2214671A1 Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
08/11/2010EP2097373B1 Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl )
08/11/2010EP1911763B1 Compositions for the treatment of gastrointestinal disorders
08/11/2010EP1756076B1 Hetroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
08/11/2010EP1546083B1 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them
08/11/2010EP1537099B1 Pyrrole based inhibitors of glycogen synthase kinase 3
08/11/2010EP1499294B1 Polymerized lipids modified with peptides used as delivery system for micronutrients
08/11/2010EP1135415B1 Humanized antibodies to gamma-interferon
08/11/2010CN1895547B Medicine for treating diabetes and its preparation
08/11/2010CN1875981B Injection emulsion containing breviscapinum and preparation method thereof
08/11/2010CN1840162B Compound total extract of compound cape jasmine, ginger and fermented soybean, its preparation and use
08/11/2010CN101801981A Sirtuin modulating thiazolopyridine compounds
08/11/2010CN101801968A polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine
08/11/2010CN101801965A Indole compounds as an inhibitor of cellular necrosis
08/11/2010CN101801957A pyridone gpr119 g protein-coupled receptor agonists
08/11/2010CN101801956A Method for modulating GPR119 G protein-coupled receptor and selected compounds
08/11/2010CN101801950A Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
08/11/2010CN101801933A quinolone derivative
08/11/2010CN101801921A Novel sulfamate compounds for medical use
08/11/2010CN101801461A [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
08/11/2010CN101801400A Use of yeast flakes for treating and/or preventing hyperinsulinemia
08/11/2010CN101801375A Insulin sensitisers and methods of treatment
08/11/2010CN101801373A Antidiabetic pharmaceutical composition
08/11/2010CN101801371A Process for the preparation of compounds useful as inhibitors of sglt
1 ... 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 ... 1298